News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioTie Therapies Corp. Reports Top-Line Data From Clinical Study With Nepicastat (SYN117) in Post-Traumatic Stress Disorder


12/27/2012 8:52:30 AM

Biotie today reported top-line data from a Phase 2 study evaluating its dopamine beta hydroxylase inhibitor nepicastat (SYN117) in combat veterans suffering from post-traumatic stress disorder (PTSD). The study was funded by the U.S. Department of Defense and conducted as an Investigator-initiated study in the United States using clinical trial material supplied by Biotie.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES